
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington -A Canadian study of 515 patients with atopic dermatitis showed that treatment with Elidel cream significantly reduced patients' use of medical resources over the six-month study period and had a positive impact on the quality of life of atopic dermatitis patients in all age groups examined.